In February 2025, we began fundraising specifically to support this program through www.cancer.ca/supportc3. We have been truly moved by the generosity of patients, families, and supporters across the country. Since launching this campaign, over $250,000 has been raised, with every dollar committed toward molecular testing. Through our partnerships, each test costs approximately $2,000, meaning that more than $500,000 has been invested into the C3 Molecular Testing Program, enabling us to sequence over 250 patients nationwide.

​

We share the closure of this testing program with great disappointment, knowing how important this program has been to our community. We wish we could sustain this program indefinitely, but as awareness of C3 grew, so did the demand for testing, and we are unable to meet the increasing need through fundraising alone.

​

That said, this is far from the end of the story. While this chapter is closing, our advocacy work is just beginning. Patients who received testing through the C3 were also enrolled in our Patient Registry, and we will use this de-identified data to clearly demonstrate the real and urgent benefit that molecular testing provides for people with biliary tract cancer.

​

We are actively working alongside our physician network and fellow patient advocacy organizations including CHCC, CCRAN, Cancertainty, and CCAF, to push for publicly funded, reflex molecular testing to become part of standard care in Canada. We will also need your voices to help ensure this message is heard by provincial decision-makers.

​

In the meantime, we will continue to gather and share information on all available pathways to access molecular testing in Canada until testing becomes routinely available for all patients. Please check back on this website in early 2026 for updated resources and guidance.

​

While the C3 Molecular Testing Program will conclude at the end of 2025, we remain hopeful that what comes next will lead to lasting, systemic change. As we transition into this next phase, any funds raised after December 31, 2025 will support C3’s ongoing operations, including the Patient Registry, research initiatives, and continued advocacy efforts.

​

Together, we have shown what is possible and together, we will keep pushing forward.

 

 

If you have any questions, suggestions or comments, please email us at info@cholangio.ca